Rhumbline Advisers Sells 34,365 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Rhumbline Advisers decreased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 9.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 345,979 shares of the biotechnology company's stock after selling 34,365 shares during the quarter. Rhumbline Advisers owned 0.25% of Arrowhead Pharmaceuticals worth $4,408,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Xponance Inc. raised its position in shares of Arrowhead Pharmaceuticals by 4.5% in the 4th quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company's stock valued at $327,000 after buying an additional 744 shares in the last quarter. Summit Investment Advisors Inc. increased its stake in Arrowhead Pharmaceuticals by 2.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company's stock valued at $714,000 after acquiring an additional 803 shares during the last quarter. ADAR1 Capital Management LLC raised its position in Arrowhead Pharmaceuticals by 10.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company's stock valued at $243,000 after purchasing an additional 1,195 shares in the last quarter. Van ECK Associates Corp lifted its stake in Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Arrowhead Pharmaceuticals by 0.8% in the 4th quarter. Swiss National Bank now owns 220,000 shares of the biotechnology company's stock valued at $4,136,000 after purchasing an additional 1,700 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $11.49, for a total value of $583,692.00. Following the transaction, the chief executive officer now directly owns 3,921,255 shares of the company's stock, valued at $45,055,219.95. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Price Performance

ARWR traded down $0.20 on Tuesday, reaching $15.50. The stock had a trading volume of 2,035,381 shares, compared to its average volume of 1,535,302. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $2.14 billion, a price-to-earnings ratio of -11.07, a price-to-earnings-growth ratio of 18.47 and a beta of 0.96. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $30.41. The firm has a 50-day moving average of $14.44 and a 200-day moving average of $17.05.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same quarter last year, the firm posted ($1.02) earnings per share. As a group, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analysts Set New Price Targets

ARWR has been the topic of several recent analyst reports. Chardan Capital reiterated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. Citigroup lowered their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Finally, Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $43.71.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.